Efficacy, Safety and Tolerability Evaluation of Global Healing Center-s Oxy Powder® in Treating Irritable Bowel Syndrome (Constipation - Predominant) (IBS-C)

Authors

  • JOGENDER K. LALLA
  • DEVEN V.PARMAR
  • MEENA U.SHAH
  • EDWARD III GROUP

Keywords:

GHC Oxy Powder®, Dietary supplement vs. Dulcolax– IBS–C Clinical Trial – Rome ll Criteria – ICH E6 GCP Guidelines– WMA Declaration of Helsinki – Drug Rules Schedule Y (Amendment 2005)

Abstract

An open, randomized, comparative, Phase II clinical trial on 20 patients with Constipation – Predominant Irritable Bowel Syndrome (IBS–C) was conducted for 6 weeks for evaluating safety, tolerability and efficacy of Oxy Powder® (OP) compared with Dulcolax (DX) tablets. The results indicated that complete cure was obtained in 30.8% and improvement in 69.2% patients treated with OP. In case of DX, improvement was seen in 71.4% patients and failure in 28.6% patients. There was no failure in case of OP indicating that efficacy of OP in treating IBS–C was significantly higher (p<.05) than DX.  

Downloads

Published

30.06.2010

How to Cite

JOGENDER K. LALLA, DEVEN V.PARMAR, MEENA U.SHAH, & EDWARD III GROUP. (2010). Efficacy, Safety and Tolerability Evaluation of Global Healing Center-s Oxy Powder® in Treating Irritable Bowel Syndrome (Constipation - Predominant) (IBS-C). International Journal of Pharma and Bio Sciences, 1(2), 1–14. Retrieved from https://ijpbs.net/index.php/journal/article/view/305

Issue

Volume 1, Issue 2, 2010

Section

Research Articles